PMID- 36075194 OWN - NLM STAT- MEDLINE DCOM- 20221206 LR - 20230106 IS - 1421-9867 (Electronic) IS - 0012-2823 (Print) IS - 0012-2823 (Linking) VI - 103 IP - 6 DP - 2022 TI - Analysis of Barrett's Esophagus and Its Risk Factors: A Cross-Sectional Study of 10,122 Subjects at a Japanese Health Examination Center. PG - 411-420 LID - 10.1159/000526154 [doi] AB - INTRODUCTION: Helicobacter pylori eradication is expected to significantly change the prevalence of Barrett's esophagus (BE). However, few reports on this relationship exist. We analyzed the risk factors of BE using the current consensus on length of BE considering H. pylori infection status. METHODS: We analyzed 10,122 individuals (5,962 men; mean age = 52.9 +/- 9.9 years) who had undergone esophagogastroduodenoscopy as part of a medical checkup. Correlations among factors including H. pylori infectious status, endoscopic findings, and BE >/=1 cm were analyzed. RESULTS: Prevalence of BE, long-segment BE, and esophageal adenocarcinoma was 22.5%, 0.014%, and 0%, respectively. Logistic regression analysis showed that the risk factors for BE were hiatal hernia (odds ratio [OR]: 2.89 [2.59-3.24]), female sex (OR: 0.52 [0.46-0.59]), social drinking (OR:0.77 [0.68-0.87]), H. pylori eradication therapy (OR: 1.34 [1.19-1.51]), proton pump inhibitor (PPI) use (OR: 1.52 [1.18-1.96]), bile reflux (OR: 1.18 [1.04-1.33]), age >/=50 years (OR: 1.13 [1.02-1.26]), and nonsteroidal anti-inflammatory drug (NSAID) use (OR: 1.29 [1.02-1.62]). Although reflux esophagitis (RE) was more common in H. pylori-negative patients (17.2%) than in those after H. pylori eradication therapy (11.8%, p < 0.00001), the latter was correlated with BE, disputing RE as a strong risk factor for BE. Therefore, we conducted a subgroup analysis; most of the risk factors except for PPI use (p = 0.75), H2-receptor antagonist use (p = 0.078), and atrophic gastritis absence (p = 0.72) were positively correlated with BE after H. pylori eradication therapy compared with H. pylori-negative status. CONCLUSIONS: H. pylori eradication, bile reflux, PPI use, and NSAID use were risk factors for BE along with hiatal hernia, male sex, and older age. CI - (c) 2022 The Author(s). Published by S. Karger AG, Basel. FAU - Kubota, Dai AU - Kubota D AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, kubota-tuk@umin.ac.jp. FAU - Takahashi, Yu AU - Takahashi Y AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Yamamichi, Nobutake AU - Yamamichi N AD - Center for Epidemiology and Preventive Medicine, The University of Tokyo Hospital, Tokyo, Japan. FAU - Matsui, Maki AU - Matsui M AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Shimamoto, Takeshi AU - Shimamoto T AD - Kameda Medical Center Makuhari, Chiba, Japan. FAU - Minatsuki, Chihiro AU - Minatsuki C AD - Infection Control and Prevention Service, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Nakagawa, Hideki AU - Nakagawa H AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Mizutani, Satoru AU - Mizutani S AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Tsuji, Yosuke AU - Tsuji Y AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Sakaguchi, Yoshiki AU - Sakaguchi Y AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Tamura, Naoki AU - Tamura N AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Yakabi, Seiichi AU - Yakabi S AD - Center for International Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Ohki, Daisuke AU - Ohki D AD - Infection Control and Prevention Service, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Mizutani, Hiroya AU - Mizutani H AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Niimi, Keiko AU - Niimi K AD - Center for Epidemiology and Preventive Medicine, The University of Tokyo Hospital, Tokyo, Japan. FAU - Wada, Ryoichi AU - Wada R AD - Kameda Medical Center Makuhari, Chiba, Japan. FAU - Fujishiro, Mitsuhiro AU - Fujishiro M AD - Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20220908 PL - Switzerland TA - Digestion JT - Digestion JID - 0150472 RN - 0 (Proton Pump Inhibitors) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) SB - IM MH - Humans MH - Male MH - Female MH - Adult MH - Middle Aged MH - *Barrett Esophagus/diagnosis/epidemiology MH - Cross-Sectional Studies MH - *Hernia, Hiatal/epidemiology MH - *Bile Reflux/complications/drug therapy MH - Japan/epidemiology MH - *Helicobacter Infections/complications/drug therapy/epidemiology MH - *Helicobacter pylori MH - *Esophagitis, Peptic/drug therapy MH - Proton Pump Inhibitors/therapeutic use MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Risk Factors PMC - PMC9808710 OTO - NOTNLM OT - Barrett's esophagus OT - Bile reflux OT - Helicobacter pylori OT - Helicobacter pylori eradication COIS- All authors declare no conflicts of interest. EDAT- 2022/09/09 06:00 MHDA- 2022/12/07 06:00 PMCR- 2022/09/08 CRDT- 2022/09/08 18:22 PHST- 2022/04/12 00:00 [received] PHST- 2022/07/18 00:00 [accepted] PHST- 2022/09/09 06:00 [pubmed] PHST- 2022/12/07 06:00 [medline] PHST- 2022/09/08 18:22 [entrez] PHST- 2022/09/08 00:00 [pmc-release] AID - 000526154 [pii] AID - dig-0103-0411 [pii] AID - 10.1159/000526154 [doi] PST - ppublish SO - Digestion. 2022;103(6):411-420. doi: 10.1159/000526154. Epub 2022 Sep 8.